|Day Low/High||198.78 / 204.78|
|52 Wk Low/High||94.26 / 200.93|
With the weekly close under the $120 support level, the next chart support lies around $90 -- the lows of 2014.
Cutthroat competition is good for customers, but not shareholders.
Pluristem's successful stem cell trial last week on muscle injuries is an important first step for the company, says the company's CEO Zami Aberman.
Here are two quality names in the sector to watch for a pullback.
Here are some less-followed names in Joel Greenblatt's portfolio.
Ziopharm, AP Pharma and Biogen Idec will headline a very big week of approval decisions, Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg.
These three holdings offer consistent earnings growth and impressive returns on invested capital.
United Therapeutics and PharMerica have strong insider buying and should perform in a turbulent market.